Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its experimental gene therapies. The company confirmed that a 51-year-old, non ...

Sarepta Therapeutics (NASDAQ:SRPT) has announced the sale of about 9.3M shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in ...

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SRPT to Cut Costs & Focus on siRNA Pipeline Last week, Sarepta announced a major restructuring plan aimed at improving long-term financial sustainability. The company will cut 36% of the workforce ...

Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:SRPT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics division, recently witnessed sharp increases in their share prices on Tuesday ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sarepta Therapeutics Inc (Symbol: SRPT), where a total of 115,596 contracts have traded ...

Sarepta Therapeutics (NASDAQ:SRPT) has hired a lobbying firm with close ties to the Trump administration as regulatory ...

Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.